Zealand Pharma A/S (NASDAQ:ZEAL) Q2 2020 Earnings Conference Call - Final Transcript
Aug 13, 2020 • 10:00 am ET
Ladies and gentlemen, thank you for standing by, and welcome to the Zealand Pharma Results for Q2 2020 Call. [Operator Instructions] After the speaker presentation there will be a question and answer session. [Operator Instructions].
I would now like to hand the conference over to your speaker today, Mads Kronborg. Please go ahead, sir.
Thank you, operator. Welcome, and thank you for joining us today to discuss Zealand's first half of 2020 financial results. I'm Mads Kronborg, Head of Investor Relations and Communications at Zealand.
With me today are Zealand's Chief Executive Officer, Emmanuel Dulac; Chief Financial Officer, Matt Dallas; and Chief Medical Officer, Adam Steensberg. The team will respectively provide business, financial and development highlights from the first half of 2020. After the prepared remarks, we will open the call to take your questions.
You can find our first half of 2020 interim report, the related company announcement and additional supporting information on our website at zealandpharma.com. As the company headquartered in Denmark, our financials are reported in Danish krone, also referred to as kroner. Key figures may have been converted to US dollars for convenience.
I would like to point out that we will be making forward-looking statements that are subject to risks and uncertainties. These statements are valid only as of today, and the company assumes no obligation to update them except as required by law. Please refer to recent filings for a more complete picture of risks and other factors.
With that, I will turn the call over to CEO, Emmanuel Dulac.
Thank you, Mads, and thanks to everyone for joining today. As announced last week, Mads joined Zealand earlier this month as the Head of Investor Relations and Communication. And we are very happy to have recruited such a strong and experienced professional to help us continue to build our organization.
Turning to slide three. Zealand has had a very strong first half of 2020 despite the unprecedented situation created by the COVID-19 pandemic. We have made significant progress towards our goal of becoming a fully integrated biotech company by leveraging our innovative pipeline to address unmet medical needs in metabolic and gastrointestinal disease.
Notably, the new drug application for the dasiglucagon HypoPal rescue pen was accepted in May and is under review by the US FDA with a target PDUFA date of March 27, 2021. As we await an approval decision, we accelerated the build-out of our commercial team. First, through the acquisition of the Valeritas assets and commercial infrastructure, including the already marketed V-Go device. And second, with strategic investments made to strengthen our commercial presence with the establishment of a new US headquarters in Boston and the appointment of Frank Sanders, our new President of Zealand Pharma US.
With four late-stage assets, we also continue to execute on our clinical development pipeline. I'm proud to share that we now completed the recruitment of our first Phase III trial for children with CHI. Fueled by the commitment to make a difference for these children